Mathematical modelling and biostatistics company Physiomics (LON: PYC) director Mike Whitlow bought 3 million shares at 0.45p/share. He owns 13%. The share price jumped 15.8% to 0.55p.
CloudCoCo (LON: CLCO) chairman Simon Duckworth bought 7.5 million shares at 0.165p each. His total shareholding in the IT company is 22.2%. The share price increased 9.09% to 0.18p.
Richmond Hill Resources (LON: RHR) has completed the field reconnaissance and rock sampling programme across the Martello Gold Project in Ontario, Canada. In the Sakoose area it appears that multiple quartz vein systems may be present. Samples are being assessed and results are expected by the end of September. The share price gained 5.66% to 1.4p.
Defence software and training provider Pennant International (LON: PEN) increased interim revenues 31% to £5.9m and gross margin improved. Annualised recurring revenues are £2.6m. The interim loss reduced from £1.7m to £300,000. Full year revenues are expected to rise from £9.7m to £13m and the company could achieve breakeven. The share price improved 5.36% to 29.5p.
Buccaneer Energy (LON: BUCE) is averaging production of 135 barrels of oil per day at the Pine Mills field in East Texas. In May, this generated $250,000 in cash flow. This is helping to pay down debt. Production could grow to 250 barrels of oil per day in the near term. There is potential for infill drilling. The share price is 5.26% higher at 0.01p.
FALLERS
Following last week’s positive trading statement medical imaging and analytics provider Ixico (LON:IXI) has announced that two Huntington’s Disease asset developments have been ended by their sponsors. Ixico was providing imaging services to these developments, and it will reduce its order book by £1.5m. The order book is still 21% ahead of one year ago. Management still expects to achieve the upgraded forecast from Cavendish. Full year revenues should be at least £8m, compared with previous estimates of £7.5m. The forecast loss was reduced to £2.9m. Year-end cash will be around £10.2m. The share price slipped 13.5% to 8p.
Pharmacogenetic testing company Genedrive (LON: GDR) expects full year revenues to rise from £1m to £1.4m. At the end of June 2026, cash was £3m. The monthly cost base is £500,000. The company has a strong foundation on which it can build. The share price fell 3.92% to 1.225p.
Hospital infections prevention technology developer Ondine Biomedical (LON: OBI) says results from the LANTERN Phase 3 pivotal study of the company’s non-antibiotic nasal photodisinfection technology should be reported within six weeks. There have been delays because of the scale of the data. The share price declined 3.45% to 14p.
Brave Bison (LON: BBSN) announced an indicative offer for market research services provider System1 Group (LON: SYS1) valuing it at £43m. Brave Bison already owns 28% bought from System1 founder John Kearon for shares and on the market for £1.3m in cash (210p/share) in March. The possible offer is 68p in cash and 2.7553 Brave Bison shares for each System1 share, which was equivalent to 327p/share at the previous closing price for Brave Bison. System1 had already rejected an earlier offer and has also rejected this one, which comes at a time when trading is improving and the dividend is growing. The bid values System1 at around 14 times prospective earnings. The Brave Bison share price is down 3.87% to 87p, while System1 is up 0.98% to 308p.